Clinical Trial Search

Primary: Expression of Glucagon Like Peptide -1 (GLP-1) and Gastric Inhibitory Peptide (GIP) Receptors in Normal Human Platelets — 3.73; 4.42 percentage of positive cells — p=0.04

Primary: Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx — 160.93 PRU

Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min

Primary: Glucagon-like Peptide-1 Secretion After Meal Ingestion — 0.82; 1.24 nmol/l/min

Primary: Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period — 2.1; 2.5; 27.5; 30.3 mg/kg/day

Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation

Primary: P2Y12 Reaction Units — 83; 52 PRU — p=0.022

Primary: Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) — 5678; 5557 [mg*min/dL]

Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05

Primary: the Relative Increase in Meal-induced Total GLP-1 Secretion — 2591; 3959 pM x 120 min

Primary: Change in Flow-mediated Dilation — 0.71; 2.06; 1.24; 0.48 Percentage

Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL

Primary: Maximal Platelet Aggregation in DM — 65; 78 percentage of aggregation — p=>0.05

Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05

Primary: Glucagon Response to Meal — 39.0; 38.8 nmol/l min

Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period

Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L

Primary: Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2 — 11.2; 5.3 mmol/L/4d

Primary: Apolipoprotein B48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo) — 122.9; 60.6 ug/kg/day

Primary: Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP) — 30; 30; 18; 17 %PRI

Primary: Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50% — 67.5; 67.2 PRI%

Primary: Forearm Blood Flow — 1.72; 2.29; 1.17; 1.63 mL/min/100 mL

Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation

Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP

Primary: Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment — -0.18; 0.14; -0.08; -0.03 mg/kg.min

Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml

Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l

Primary: Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. — 11.8; 11.2; 11.6; 11.5 m/s

Primary: Platelet Reactivity Defined by VerifyNow PRU in HPR and NPR Patients — 219; 241; 141; 159 PRU — p=0.169

Primary: Insulin Secretion — 56766 pmol/l * 90 minutes